Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Ireland

European Innovation Council · Finished

PAH-Advance PAH-ADVANCE: Accelerating the Clinical Path of NTP42, a disease-modifying drug that will disrupt the future treatment of cardiopulmonary diseases, including pulmonary arterial hypertension (PAH).

Coordinator
Atxa Therapeutics Ltd, Ireland
Runs
1 January 2023 to 31 December 2023
Status
Finished
EU funding
€2.5m
Total cost
€4.2m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190143893

What the project is doing

In the project's own words, from its summary on CORDIS.

ATXA Therapeutics has developed NTP42, a disruptive new drug for pulmonary arterial hypertension (PAH) and related cardiopulmonary (heart & lung) diseases. NTP42 blocks the thromboxane receptor, a target at the root cause of PAH & related diseases. By treating all clinical hallmarks in both the LUNGS and HEART, NTP42 offers a game-changing solution for PAH leading to its rapid adoption once marketed. ATXAs Phase I clinical trial showed NTP42 is safe & highly efficacious in man.

With EIC Blended Finance and VC co-investment, ATXA will undertake a Phase II trial on NTP42 in PAH. We will then secure a licensing deal with a pharma to ACCELERATE NTP42 to the PAH market (sales >$1B at 5 yrs post-launch & royalty returns to ATXA). With the proceeds of the licensing deal, we will DIVERSIFY uses of NTP42/pipeline drugs to treat other priority target diseases. This will also ENABLE growth (>100 FTEs), transforming ATXA into a major European pharma with a diversified diseases & drugs portfolio.

Topics

Who is involved

OrganisationCityCountryRole
Atxa Therapeutics LtdDublinIrelandCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI